|
2024
|
Invention
|
Rnai induced c9orf72 suppression for the treatment of als/ftd.
The present invention provides fo... |
|
|
P/S
|
Viral systems, gene therapy systems, and nucleic acid delivery systems, all comprised of biologic... |
|
|
P/S
|
Viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vect... |
|
2023
|
Invention
|
Aav capsid production in insect cells.
The present invention relates to the production of adeno-... |
|
|
Invention
|
Vectors with modified initiation codon for the translation of aav-rep78 useful for production of ... |
|
2022
|
P/S
|
Medical training and teaching medical information; medical counselling; medical consultations; me... |
|
|
P/S
|
Medical education services; Medical tuition services; Medical training and teaching. Medical info... |
|
|
Invention
|
Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof.
The present invent... |
|
|
Invention
|
Means and methods for aav gene therapy in humans.
The present invention relates to means and met... |
|
|
Invention
|
Rnai induced huntingtin gene suppression.
The present invention provides for a double stranded R... |
|
|
Invention
|
Aav vectors produced by insect cells comprising rep52 and rep78 coding sequences with differentia... |
|
|
Invention
|
Targeting misspliced transcripts in genetic disorders.
The present invention relates to repeat e... |
|
2021
|
P/S
|
Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System disea... |
|
|
Invention
|
Immunoadsorption.
Upon administration of rAAV vectors the humoral immune response (neutralizing ... |
|
|
Invention
|
Companion diagnostic to monitor the effects of gene therapy.
The invention relates to the field ... |
|
|
Invention
|
Liver-specific viral promoters and methods of using the same.
The present invention relates to p... |
|
|
Invention
|
Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3.
The curre... |
|
|
Invention
|
Method and means to deliver mirna to target cells.
The invention relates to the field of gene th... |
|
|
Invention
|
Dna impurities in a composition comprising a parvoviral virion.
The current invention relates to... |
|
|
Invention
|
Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof. The present inventi... |
|
2020
|
Invention
|
Further improved aav vectors produced in insect cells.
The present invention relates to the prod... |
|
|
Invention
|
Targeting misspliced transcripts in genetic disorders. The present invention relates to repeat ex... |
|
|
Invention
|
Rnai induced huntingtin gene suppression. The present invention provides for a double stranded RN... |
|
|
Invention
|
Modified viral vectors and methods of making and using the same. The present invention relates to... |
|
|
P/S
|
Pharmaceutical products; pharmaceutical preparations and vaccines for use in gene therapy and cel... |
|
|
P/S
|
Pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological pre... |
|
|
Invention
|
Methods of improving adeno-associated viral transduction. Described herein are saturating agents,... |
|
|
Invention
|
Aav capsid production in insect cells. The present invention relates to the production of adeno-a... |
|
2019
|
Invention
|
Method and means to deliver mirna to target cells. The invention relates to the field of gene the... |
|
|
Invention
|
Liver-specific viral promoters and methods of using the same. The present invention relates to pr... |
|
|
Invention
|
A companion diagnostic to monitor the effects of gene therapy. The invention relates to the field... |
|
|
Invention
|
Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3. The curren... |
|
|
Invention
|
Rnai induced c9orf72 suppression for the treatment of als/ftd. The present invention provides for... |
|
|
Invention
|
Mutated rep encoding sequences for use in aav production. Nucleic acids encoding Parvoviral Rep p... |
|
|
Invention
|
Immunoadsorption. Upon administration of rAAV vectors the humoral immune response (neutralizing a... |
|
|
P/S
|
Medicinal preparations for treatment of hemophilia A, namely, viral systems, gene therapy systems... |
|
|
P/S
|
Viral systems, gene therapy systems, nucleic acid delivery
systems, viral vectors, non-viral vec... |
|
|
Invention
|
Removal of contaminating viruses from aav preparations.
The present invention relates to a separ... |
|
2018
|
Invention
|
Improved aav capsid production in insect cells. The present invention relates to the production o... |
|
|
Invention
|
Means and methods for aav gene therapy in humans. The present invention relates to means and meth... |
|
2017
|
Invention
|
Immunoadsorption. Upon administration of r AAV vectors the humoral immune response (neutralizing ... |
|
|
Invention
|
Removal of contaminating viruses from aav preparations. The present invention relates to a separa... |
|
2015
|
Invention
|
Dna impurities in a composition comprising a parvoviral virion. The current invention relates to ... |
|
|
P/S
|
Pharmaceutical products; biological preparations for use in
medical and clinical gene therapy an... |
|
|
Invention
|
Further improved aav vectors produced in insect cells. The present invention relates to the produ... |
|
2014
|
P/S
|
Biological preparations for use in medical and clinical gene therapy and cell therapy; clinical m... |
|
2013
|
P/S
|
[Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, ge... |
|
2011
|
P/S
|
Viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vec... |
|
2007
|
P/S
|
Pharmaceutical products; biological preparations for use in medical and clinical gene therapy and... |
